​

Biogen (BIIB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIIB Stock Forecast

Biogen (BIIB) stock forecast, based on 48 Wall Street analysts, predicts a 12-month average price target of $218.16, with a high of $260.00 and a low of $185.00. This represents a 9.10% increase from the last price of $199.96.

$150 $180 $210 $240 $270 $300 High: $260 Avg: $218.16 Low: $185 Last Closed Price: $199.96

BIIB Stock Rating

Biogen stock's rating consensus is Buy, based on 48 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 29 Buy (60.42%), 18 Hold (37.50%), 1 Sell (2.08%), and 0 Strong Sell (0.00%).

Buy
Total 48 1 18 29 Strong Sell Sell Hold Buy Strong Buy

BIIB Price Target Upside V Benchmarks

TypeNameUpside
StockBiogen9.10%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks9.12%

Price Target Trends

1M3M12M
# Anlaysts31039
Avg Price Target$235.67$225.50$204.90
Last Closing Price$199.96$199.96$199.96
Upside/Downside17.86%12.77%2.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26218151-36
May, 26317161-37
Apr, 26114201-36
Mar, 26114201-36
Feb, 26214181-35
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 08, 2026Needham$255.00$195.3430.54%27.53%
May 27, 2026Brian AbrahamsRBC Capital$227.00$193.0817.57%13.52%
May 15, 2026Piper Sandler$225.00$191.3717.57%12.52%
Apr 30, 2026Morgan Stanley$206.00$188.769.13%3.02%
Apr 30, 2026Brian AbrahamsRBC Capital$222.00$190.7816.36%11.02%
Apr 30, 2026Wedbush$196.00$194.380.83%-1.98%
Apr 30, 2026Guggenheim$260.00$194.3833.76%30.03%
Apr 20, 2026Mohit BansalWells Fargo$250.00$177.3540.96%25.03%
Apr 14, 2026Piper Sandler$214.00$176.3721.34%7.02%
Apr 10, 2026Morgan Stanley$200.00$173.4815.29%0.02%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 08, 2026NeedhamBuyBuyupgrade
May 27, 2026RBC CapitalOutperformOutperformhold
May 15, 2026Piper SandlerOverweightOverweighthold
May 14, 2026H.C. WainwrightBuyBuyhold
May 01, 2026CitigroupNeutralNeutralhold
Apr 30, 2026RBC CapitalOutperformOutperformhold
Apr 30, 2026WedbushNeutralNeutralhold
Apr 30, 2026GuggenheimBuyBuyhold
Apr 20, 2026Wells FargoBuyOverweightupgrade
Apr 14, 2026Piper SandlerNeutralOverweightupgrade

Financial Forecast

EPS Forecast

$5 $10 $15 $20 $25 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.44$20.97$8.02$11.20$8.85---
Avg Forecast$19.19$17.11$14.99$16.42$16.48$17.37$18.95$20.72
High Forecast$20.57$18.68$15.57$17.18$20.03$25.69$26.87$23.62
Low Forecast$18.00$15.76$14.74$16.13$14.45$13.83$15.13$18.61
Surprise %-45.60%22.56%-46.50%-31.79%-46.30%---

Revenue Forecast

$9B $9B $10B $10B $11B $12B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.98B$10.17B$9.84B$9.68B$9.81B---
Avg Forecast$10.87B$10.07B$9.93B$9.63B$9.43B$9.56B$9.92B$10.14B
High Forecast$11.47B$10.78B$10.08B$9.74B$10.42B$9.57B$9.94B$11.23B
Low Forecast$10.35B$9.46B$9.78B$9.55B$8.69B$9.56B$9.89B$9.35B
Surprise %1.01%1.00%-0.93%0.43%4.04%---

Net Income Forecast

$500M $1B $2B $3B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.56B$3.05B$1.16B$1.63B$1.29B---
Avg Forecast$1.37B$1.82B$1.16B$2.42B$2.51B$2.37B$2.56B$3.02B
High Forecast$1.64B$2.18B$1.39B$2.50B$2.92B$3.74B$3.91B$3.44B
Low Forecast$1.09B$1.46B$928.88M$2.35B$2.10B$2.01B$2.20B$2.71B
Surprise %13.84%67.40%--32.69%-48.48%---

BIIB Forecast FAQ

Is Biogen stock a buy?

Biogen stock has a consensus rating of Buy, based on 48 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 29 Buy, 18 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Biogen is a favorable investment for most analysts.

What is Biogen's price target?

Biogen's price target, set by 48 Wall Street analysts, averages $218.16 over the next 12 months. The price target range spans from $185 at the low end to $260 at the high end, suggesting a potential 9.10% change from the previous closing price of $199.96.

How does Biogen stock forecast compare to its benchmarks?

Biogen's stock forecast shows a 9.10% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (9.12%).

What is the breakdown of analyst ratings for Biogen over the past three months?

  • June 2026: 5.56% Strong Buy, 50.00% Buy, 41.67% Hold, 2.78% Sell, 0% Strong Sell.
  • May 2026: 8.11% Strong Buy, 45.95% Buy, 43.24% Hold, 2.70% Sell, 0% Strong Sell.
  • April 2026: 2.78% Strong Buy, 38.89% Buy, 55.56% Hold, 2.78% Sell, 0% Strong Sell.

What is Biogen’s EPS forecast?

Biogen's average annual EPS forecast for its fiscal year ending in December 2026 is $17.37, marking a 96.27% increase from the reported $8.85 in 2025. Estimates for the following years are $18.95 in 2027, and $20.72 in 2028.

What is Biogen’s revenue forecast?

Biogen's average annual revenue forecast for its fiscal year ending in December 2026 is $9.56B, reflecting a -2.51% decrease from the reported $9.81B in 2025. The forecast for 2027 is $9.92B, and $10.14B for 2028.

What is Biogen’s net income forecast?

Biogen's net income forecast for the fiscal year ending in December 2026 stands at $2.37B, representing an 83.24% increase from the reported $1.29B in 2025. Projections indicate $2.56B in 2027, and $3.02B in 2028.